SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

PharmaTher Develops Colon-Targeted KPV and BPC-157 Products

PharmaTher says it is developing colon-targeted KPV and BPC-157 products for a new US peptide pathway.

Related stories